Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

51 results about "Inhalation Solution" patented technology

Polymyxin inhalation liquid preparation and preparation method thereof

ActiveCN119523952Asimple compositionreduce spasmsPowder deliverySpray deliveryBronchospasmInhalation
The invention relates to a polymyxin inhalation liquid preparation and a preparation method thereof. The polymyxin inhalation liquid preparation comprises 0.1-5% (W / V) of polymyxin B sulfate, 0.05-1% (W / V) of a stabilizer, 0.1-0.9% (W / V) of an osmotic pressure regulator, a pH value regulator and a solvent, the pH (Potential of Hydrogen) of the liquid preparation is 3.0 to 6.0; the solvent is selected from purified water and water for injection; the polymyxin inhalation solution provided by the invention is simple in composition, the pH value of the polymyxin inhalation solution is 3.0-6.0, osmotic pressure and isotonic pressure are simultaneously realized, bronchus spasm and cough caused by the polymyxin inhalation solution can be reduced, safety evaluation verifies that the polymyxin inhalation solution has better safety, and a new choice is provided for clinical application.
Owner:THE FOURTH HOSPITAL OF HEBEI MEDICAL UNIVERSITY (HEBEI CANCER HOSPITAL) +1

Impurity analysis method for budesonide inhalation solution

The invention discloses an impurity analysis method for a budesonide inhalation solution, and relates to the technical field of budesonide impurity analysis, and the method comprises the following steps: weighing 50mg of a budesonide inhalation solution sample, placing the budesonide inhalation solution sample in a 10mL volumetric flask, adding a diluent (such as acetonitrile and methanol) to a scale line, and fully shaking to dissolve the diluent to prepare a 5mg / mL sample solution; and filtering the diluted sample by using a filter so as to remove insoluble impurities. According to the budesonide inhalation solution impurity analysis technology, the product quality, the market competitiveness and the research and development capability of enterprises can be remarkably improved, meanwhile, the requirements of laws and regulations are met, and time and cost are saved; by analyzing the impurities, the product quality and safety can be improved, and by accurately analyzing and controlling the impurity content in the medicine, the purity and quality of the product can be remarkably improved, so that the risk of adverse reaction and side effect can be reduced, and the medication safety of a patient is improved.
Owner:ZHEJIANG FURUIXI PHARM CO LTD

UPLC (Ultra Performance Liquid Chromatography) analysis method of levosalbutamol hydrochloride inhalation solution

The invention relates to the technical field of ultra-high performance liquid chromatography, in particular to an ultra-high performance liquid chromatography (UPLC) analysis method of a levosalbutamol hydrochloride inhalation solution. The detection method comprises the following steps: detecting levosalbutamol and related substances in a levosalbutamol hydrochloride inhalation solution; the related substances comprise an impurity A, an impurity B, an impurity C, an impurity D, an impurity E, an impurity F, an impurity G and an impurity H; the detection method adopts ultra-high performance liquid chromatography, and the chromatographic conditions are as follows: octadecylsilane chemically bonded silica is used as a filler; a phosphoric acid aqueous solution with the mass percent of 0.05-0.1% is used as a mobile phase A, and methanol-acetonitrile-water-phosphoric acid is used as a mobile phase B; the detection wavelength is 215 to 225 nm; the column temperature is 40-50 DEG C; the flow velocity is 0.5 to 0.7 mL / min; according to the method, eight impurities can be simultaneously detected and can be effectively separated; the method has the advantages of sensitivity, exclusiveness, accuracy, high efficiency, convenience, low cost and the like, the detection process is completed within 15 minutes, and the efficiency is high. According to the method disclosed by the invention, the contents of the levosalbutamol and the related substances can be effectively controlled, and a basis is provided for quality control of the levosalbutamol hydrochloride inhalation solution, so that the clinical curative effect of the levosalbutamol hydrochloride inhalation solution is ensured.
Owner:SHANDONG DYNE FINANCIAL HLDG CHILDRENS PHARM CO LTD

A modified bromhexine hydrochloride inhalation solution with enhanced stability and a method for its preparation

The application discloses a modified bromhexine hydrochloride inhalation solution with enhanced stability and a preparation method thereof, and belongs to the technical field of medical preparations. The inhalation solution is mainly prepared from a targeting impurity control modified bromhexine hydrochloride inclusion compound, a special composite buffer mother liquor for inhibiting impurity B, inhalation grade sodium chloride, pharmaceutical grade sodium hydroxide and water for injection, and the pH value of the finished product is 4.5-5.5. The application constructs a three-stage progressive modification system, covalently grafts a mercapto-activated L-cysteine derivative onto hydroxypropyl-gamma-cyclodextrin to prepare a functional carrier, and realizes molecular-level isolation of bromhexine hydrochloride through host-guest inclusion, thereby blocking the generation of impurity B of bromhexine hydrochloride from the whole path, and solving the core pain points of easy impurity exceeding, short effective period and airway irritation of the existing product. The application can realize long-acting stable storage for 36 months, is suitable for the existing industrial production line, and has high clinical application and industrialization values.
Owner:HEFEI SINOPHARM NOVO PHARM CO LTD

Detection method of revienacin inhalation solution

The invention relates to a detection method of a revivacin inhalation solution, and belongs to the technical field of medicine detection. According to the detection method provided by the invention, a revivin inhalation solution sample is analyzed by adopting high performance liquid chromatography to obtain the content of impurities in the revivin inhalation solution; the high performance liquid chromatography uses a phosphate buffer as a mobile phase A and acetonitrile as a mobile phase B, and the elution conditions are as follows: 0-5 min, the volume ratio of the mobile phase A to the mobile phase B is gradually changed from 95: 5 to 80: 20; the volume ratio of the mobile phase A to the mobile phase B is gradually changed from 80: 20 to 20: 80 in 5-30 min; the volume ratio of the mobile phase A to the mobile phase B is 95: 5. The method provided by the invention can realize accurate detection of five different impurities in the revienacin inhalation solution, and is beneficial to actual production quality control and improvement of drug safety.
Owner:JIUHUA HUAYUAN PHARMACEUTICAL CO LTD

Quality control method of shuanghuanglian inhalation solution

The application relates to the field of traditional Chinese medicine quality control, and particularly discloses a quality control method for Shuanghuanglian inhalation solution. The method can simultaneously determine the fingerprint spectrum and ingredient content of the Shuanghuanglian inhalation solution. The fingerprint spectrum detection method disclosed by the application adopts UPLC determination, has 17 characteristic peaks, and attributes 8 characteristic peaks. The contents of neochlorogenic acid, chlorogenic acid, cryptochlorogenic acid, isochlorogenic acid B, isochlorogenic acid A, isochlorogenic acid C and forsythoside are simultaneously determined. Compared with the prior art, the method for determining the fingerprint spectrum and content of the Shuanghuanglian inhalation solution is improved, and the quality of the Shuanghuanglian inhalation solution can be comprehensively monitored conveniently, quickly and accurately.
Owner:INCREASEPHARM HENGQIN INST CO LTD

Application of genipin-1-beta-D gentiobioside in preparation of medicine for treating chronic obstructive pulmonary disease

The invention relates to an application of genipin-1-beta-D gentiobioside in preparation of a medicine for treating chronic obstructive pulmonary disease. The genipin-1-beta-D gentiobioside is prepared into an aerosol inhalation solution, and the aerosol inhalation administration mode is adopted, so that the lung function in the chronic obstructive pulmonary disease can be improved, the content of inflammatory factors in lung tissues can be reduced, and the lung tissue injury can be relieved.
Owner:BELETALENT (ZHUHAI) PHARMACEUTICAL CO LTD

Honeysuckle total extract inhalation solution as well as preparation method and application thereof

The invention belongs to the technical field of biological medicines, and particularly relates to a honeysuckle total extract inhalation solution as well as a preparation method and application thereof. According to the invention, the honeysuckle total extract with poor water solubility, phospholipid and chitosan are innovatively and directionally assembled into the chitosan-phospholipid nanoparticles with uniform structure, and the nanoparticles are prepared by adopting a microfluidic technology. The strategy significantly improves the water solubility and stability of the honeysuckle total extract, and successfully prepares an inhalation solution suitable for pulmonary administration based on the nanoparticle dispersion system. The obtained preparation has the characteristics of high physical stability and good bioavailability potential. The honeysuckle total extract inhalation solution provided by the invention can effectively relieve the pathological process of the pyotoxic pneumonia through multiple mechanisms of remarkably inhibiting lung inflammatory response, relieving pulmonary edema, protecting the structural integrity of pulmonary alveoli and the like. Especially, a high-dose group shows a curative effect superior to that of a positive control drug, and a good dose-effect relationship is combined, so that the preparation has remarkable development potential and clinical transformation prospect in treatment of the septic pneumonia.
Owner:SHANDONG ACADEMY OF PHARMACEUTICAL SCIENCES +1

A nintedanib solution for inhalation and a method for preparing the same

The present application provides a kind of nintedanib solution for inhalation and preparation method and application, the inhalation solution includes active substance, solvent and auxiliary material, the single dose specification of the inhalation solution is 1-5ml, and the active substance in single dose specification is 2.41-12.04mg / ml nintedanib ethanesulfonic acid;The solvent is sterile injection solution water;The auxiliary material includes isotonicity regulator and pH regulator and can also include antioxidant;The addition amount of the isotonicity regulator is to make the inhalation solution have the weight molal osmotic concentration of 240-400mOsmol / kg;The addition of the pH regulator is to make the pH value of the inhalation solution preparation 3.0-4.0.The inhalation nintedanib solution of the present application can provide a kind of nintedanib for inhalation with convenient, safe and effective, and good stability of drug dosage form and drug delivery system in combination with liquid atomization device.
Owner:INCREASEPHARM TIANJIN INST CO LTD

A pumafentrine nanosuspension inhalation solution for the treatment of interstitial pneumonitis and a process for its preparation

The application discloses a pirfenidone nanosuspension inhalation solution for treating interstitial pneumonia and a preparation method thereof, and belongs to the technical field of pharmaceutical preparations. The pirfenidone nanosuspension inhalation solution is composed of the following components in 1000ml: 8-12g of pirfenidone hydrochloride, 4-6g of polyethylene glycol-poly-L-histidine block copolymer, 45-55g of mannitol, 0.4-0.6g of antioxidant, 0.05mol / L of citric acid-sodium citrate buffer, and water for injection, wherein the amount of the citric acid-sodium citrate buffer is appropriate, and the water for injection is added to 1000ml. The application adopts a pulmonary targeted inhalation administration path of non-gastrointestinal absorption, so that the drug directly acts on the lung interstitial lesion part by bypassing the intestinal absorption link.
Owner:BEIJING MADISON PHARMACEUTICAL TECHNOLOGY CO LTD

Method for detecting nitrosamine impurities in terbutaline sulfate aerosol inhalation solution

The invention belongs to the technical field of analysis and detection, and relates to a method for detecting nitrosamine impurities in a terbutaline sulfate aerosol inhalation solution. The method comprises the following steps: diluting a terbutaline sulfate aerosol inhalation solution to obtain a test solution; detecting the test solution by adopting an ultra-high performance liquid chromatography-tandem mass spectrometry method; wherein the chromatographic conditions are as follows: a filling agent of a chromatographic column is octadecylsilane chemically bonded silica; the mobile phase A is an ammonium acetate aqueous solution; the mobile phase B is acetonitrile; the nitrosamine impurity is N-nitroso-terbutaline, and the nitrosamine impurity is N-nitroso-terbutaline. The method for detecting the N-nitroso-terbutaline impurities in the terbutaline sulfate aerosol inhalation solution by adopting the ultra-high performance liquid chromatography-tandem mass spectrometry technology is proposed for the first time, the method is high in selectivity, the quantitation limit is as low as 1.5% of the limit, the detection limit is as low as 0.5% of the limit, detection can be completed only in 10 minutes, and the method is suitable for large-scale popularization and application. Powerful guarantee is provided for effectively controlling the medicine quality and guaranteeing the medicine safety.
Owner:SHANDONG DYNE FINANCIAL HLDG CHILDRENS PHARM CO LTD

Environment-friendly treatment device for wastewater of inhalation solution medicine production line

The application discloses an inhaled solution medicine production line wastewater environment-friendly treatment device, which comprises a treatment tank, a storage tank for storing high-efficiency activated carbon powder, an agitating device for agitating liquid in the treatment tank and a stirring plate rotationally connected with the agitating device, and further comprises a material scattering device for scattering the high-efficiency activated carbon powder into the liquid for catalysis when the liquid enters the treatment tank. When the wastewater is added and enters a catalytic oxidation stage, hydrogen peroxide needs to be separately injected. If the linkage is not cut off, the liquid flow at the water inlet will trigger the blocking plate again, so that the excessive high-efficiency activated carbon enters the treatment tank. The sliding block drives the connecting rod to be displaced, so that the connecting rod is separated from the blocking plate, and mechanical limiting is realized through the key, so that the solid-liquid ratio in the tank is kept constant, and the influence of the excessive high-efficiency activated carbon on the subsequent catalysis is avoided.
Owner:SICHUAN QIYUAN PHARM CO LTD

Use of methyl parahydroxybenzoate and its sodium salt in anti-coronavirus

The present invention belongs to the field of drug therapy, and specifically relates to the use of methyl parahydroxybenzoate and its sodium salt in the preparation of drugs for treating viral infectious diseases. The present invention discloses the use of methyl parahydroxybenzoate, its sodium salt and its inhalation preparation in the treatment of coronavirus infectious diseases. By verifying the new use of methyl parahydroxybenzoate and its sodium salt inhalation solution in a mouse test infected with human coronavirus HCoV-229E, the technical solution has novelty, and an efficacy test of meta-cresol inhalation solution in treating pneumonia caused by HCoV-229E virus infection was conducted. The results showed that methyl parahydroxybenzoate and its sodium salt inhalation solution showed good efficacy in the lung index and inhibition rate of pneumonia mice infected with HCoV-229E virus, and could significantly reduce the mouse lung index.
Owner:INCREASEPHARM HENGQIN INST CO LTD

Procaterol hydrochloride inhalation solution related substance detection method

The invention relates to the technical field of substance impurity detection methods, in particular to a procaterol hydrochloride inhalation solution related substance detection method which adopts high performance liquid chromatography for detection, and chromatographic conditions are as follows: mobile phases include a mobile phase A and a mobile phase B; the mobile phase A is a phosphate buffer solution, and the mobile phase B is methanol. The method can effectively detect the related substances in the procaterol hydrochloride inhalation solution, has the advantages of strong specificity, high sensitivity and comprehensive impurity control, and can better control the quality of a preparation.
Owner:ZHEJIANG FURUIXI PHARM CO LTD

Dihydromyricetin inhalation liquid preparation and preparation method thereof

The invention relates to a dihydromyricetin inhalation liquid preparation and a preparation method thereof. The dihydromyricetin inhalation liquid preparation comprises dihydromyricetin, a stabilizer, an osmotic pressure regulator, a pH value regulator, a cosolvent and a solvent, the content of the dihydromyricetin is 0.1-2 mg / mL, the content of the stabilizer is 0.4-3 mg / mL, the content of the osmotic pressure regulator is 1-10 mg / mL, and the content of the cosolvent is 20-25% V / V; the pH (Potential of Hydrogen) of the liquid preparation is 3.0 to 6.0; according to the dihydromyricetin inhalation solution preparation provided by the invention, the bioavailability of the medicine is effectively improved, the dihydromyricetin inhalation solution preparation has the characteristics of definite medicine effect, reliable quality, high safety and the like, and the preparation method is few in steps, easy to operate and beneficial to industrial production.
Owner:HEBEI MEDICAL UNIVERSITY +1

Revivenacin inhalation solution and preparation method thereof

The invention relates to a revienacin inhalation solution and a preparation method thereof. The revienacin inhalation solution comprises revienacin, a stabilizing agent, a buffering agent and water for injection, wherein the stabilizer is disodium edetate and propylene glycol, and the mass volume ratio of the disodium edetate to the propylene glycol is (0.05-0.1) g: (50-300) ml. The revivin inhalation solution can effectively delay degradation of revivin under the high-temperature condition, the long-term stability of a preparation under the high-temperature condition is guaranteed, the preparation prescription and the preparation process are simple and easy to operate, and the revivin inhalation solution is suitable for large-scale industrial production.
Owner:TIANJIN PHARMA GROUP XINZHENG

Packaging box (formoterol fumarate)

1. Name of the designed product: package box (formoterol fumarate). 2. Use of the designed product: the designed product is used for packing formoterol fumarate inhalation solution. 3. Design points of the designed product: combination of shape and pattern. 4. Picture or photo best indicating the design points: perspective view.
Owner:JIANG SU PHARMAMAXCORP

Inhalation solution for bronchial constriction maintenance treatment of chronic obstructive pulmonary disease patient and preparation method of inhalation solution

The invention provides an inhalation solution for bronchial constriction maintenance treatment of a chronic obstructive pulmonary disease patient and a preparation method of the inhalation solution, and relates to the technical field of pharmaceutical preparations. The preparation method comprises the following steps: adding 50-95% of water for injection into a liquid preparation tank, cooling the water for injection to 50 DEG C, starting stirring, synchronously and sequentially adding sodium chloride, citric acid and sodium citrate according to the prescription dosage, stirring to dissolve the sodium chloride, the citric acid and the sodium citrate, continuously cooling to 40 DEG C, adding formoterol fumarate according to the prescription dosage, stirring to dissolve for 60 minutes, fixing the volume, and stirring again for 10 minutes for later use. According to the preparation method of the formoterol fumarate inhalation solution provided by the invention, process parameters are accurately controlled, so that the sterility guarantee level of the formoterol fumarate inhalation solution can be improved, the increase of the impurity content can be effectively controlled, and good stability of the formoterol fumarate inhalation solution is ensured.
Owner:JINYAO HEPING (TIANJIN) PHARMACEUTICAL CO LTD

Fudosteine Nebulization Inhalation Solution Composition, Medicinal Assembly and Its Application

There is provided a budesonide nebulization inhalation solution composition and its application. The composition, which is a budesonide nebulization inhalation solution composed of budesonide, a pH adjuster, and water, has, as the particle size of the spray droplets, D 90 The particle size is 7.0 to 10.0 μm, D 50 The particle size is 2.8 to 4.5 μm, D 10 The particle size is 0.5 to 1.5 μm, and the deposition percentage of particles with an aerodynamic diameter of 1.4 to 5.4 μm in the budesonide inhalation solution is 50% or more. Further provided is a medicinal assembly for use in combination with a nebulization inhalation solution, comprising an inhalation composition, a nebulizer with specific parameters, and a nebulizer cup. The budesonide nebulization inhalation solution composition and its medicinal assembly have the advantages of a small effective amount, rapid onset of effect, and high drug delivery efficiency, and are particularly effective in the treatment of tracheal and main bronchial diseases.
Owner:BEIJING INCREASE INNOVATIVE DRUG RESEARCH CO LTD

Fudosteine nebulization inhalation solution composition, drug assembly, and use thereof

A fudosteine nebulization inhalation solution composition and use thereof. The fudosteine nebulization inhalation solution consists of fudosteine, a pH-adjusting agent and water. The droplet particle size of the composition is as follows: the D90 particle size is 7.0-10.0 µm, the D50 particle size is 2.8-4.5 µm, and the D10 particle size is 0.5-1.5 µm; and the percent deposition of the particles with the aerodynamic particle size of 1.4-5.4 µm in the fudosteine inhalation solution is not less than 50%. In addition, further provided is a drug assembly for use in conjunction with the nebulization inhalation solution, comprising the inhalation composition, and a nebulizer and a nebulizing cup with specific parameters. The fudosteine nebulization inhalation solution composition and the assembly thereof have the advantages of a small effective dose, acting fast, high drug delivery efficiency, and the like, and are particularly effective in treating tracheal and main bronchial diseases.
Owner:BEIJING INCREASE INNOVATIVE DRUG RESEARCH CO LTD

Unit dose pharmaceutical composition as well as preparation method and application thereof

The present invention relates to a pharmaceutical composition of an inhalation solution comprising unit dose of indacenroguron bromide, a method for preparing the same, and a use thereof. The unit dose composition is prepared by dissolving a specific amount of active ingredients, an osmotic pressure regulator, a buffer ion pair, a pH regulator and other auxiliary material components in water, the active substances form aerosol by means of an atomizer, the aerosol is applied to asthma and COPD patients in an inhalation mode, and the unit dose composition has the advantages of being high in effectiveness, good in safety, good in patient compliance and the like.
Owner:SICHUAN HAISCO PHARMA CO LTD

Perohyclidine hydrochloride liquid preparation and quality stability control method thereof

The invention provides a penehyclidine hydrochloride liquid preparation quality stability control method and a penehyclidine hydrochloride inhalation solution thereof. The preparation is packaged by adopting a plastic package or adding sodium chloride into a glass package. The packaging method can control the pH value of the preparation. The weight ratio of the water for injection to the penehyclidine hydrochloride to the sodium chloride of the inhalation preparation is 2000: 0.5-1: 18. The preparation can be used for treating chronic obstructive pulmonary disease.
Owner:CHONGQING XIANYANG PHARMA TECH CO LTD

A levosalbutanol hydrochloride nebulized inhalation solution formulation, its preparation method, and its application.

PendingCN123101503AObstructive airway diseaseAntioxidant
This invention discloses a levosalbutamol hydrochloride nebulized inhalation solution formulation, its preparation method, and its application, belonging to the field of pharmaceutical formulation technology. The formulation comprises micronized levosalbutamol hydrochloride, a wetting agent, an isotonic regulator, a metal ion chelating agent, an antioxidant, a pH adjuster, and water for injection. The particle size distribution of the micronized levosalbutamol hydrochloride is D90 ≤ 10 μm and D50 2-5 μm. This invention significantly improves nebulization delivery efficiency by controlling the particle size distribution through micronization of the active ingredient and reducing surface tension with a wetting agent, achieving a fine particle fraction of over 65%. Simultaneously, through the synergistic effect of the antioxidant and the metal ion chelating agent, it exhibits good chemical stability under non-nitrogen-protected conditions. This invention also discloses the preparation method of the formulation and its application in the treatment of reversible obstructive airway diseases.
Owner:SUZHOU HOMESUN PHARMA CO LTD

Application of cresol in drugs for treating coronavirus infectious diseases

The present invention belongs to the field of drug therapy, and specifically relates to the use of cresol in the preparation of drugs for treating viral infectious diseases. The present invention discloses the use of cresol and its inhalation preparation in the treatment of coronavirus infectious diseases. The new use of cresol inhalation solution was verified in a mouse test infected with human coronavirus HCoV-229E. The technical solution has novelty, and the efficacy test of cresol inhalation solution in the treatment of pneumonia caused by HCoV-229E virus infection was carried out. The results showed that the cresol inhalation solution showed good efficacy in the lung index and inhibition rate of pneumonia mice infected with HCoV-229E virus, and could significantly reduce the mouse lung index.
Owner:INCREASEPHARM HENGQIN INST CO LTD

Vilanterol triphenylacetate inhalation solution and preparation method thereof

The present invention provides a solution of vilanterol triphenylacetate for inhalation, a preparation method and an application thereof, wherein the inhalation solution comprises an active substance, a solvent and an excipient. The single-dose specification of the inhalation solution is 1 ml, and the single-dose specification comprises 15 to 50 μg / mL of vilanterol triphenylacetate and / or its hydrate as an active substance; the solvent is water for sterile injection, and the excipients comprise an osmotic pressure regulator and a pH regulator, the osmotic pressure regulator has a concentration of 5 to 9 mg / ml, and the pH regulator is added to make the pH value of the inhalation solution preparation be 5.0 to 7.0. The solution of the present invention is packaged in a single dose, does not contain a preservative, is safe and convenient to use, and is used in combination with a liquid nebulizer to provide a safe, effective and stable pharmaceutical dosage form and drug delivery system for inhalation of vilanterol triphenylacetate.
Owner:BEIJING INCREASE INNOVATIVE DRUG RESEARCH CO LTD

A polymyxin inhalation liquid formulation and its preparation method

This invention relates to a polymyxin inhalation liquid formulation and its preparation method, comprising 0.1-5% (w / v) polymyxin B sulfate, 0.05-1% (w / v) stabilizer, 0.1-0.9% (w / v) osmolarity regulator, pH adjuster, and solvent; the pH of the liquid formulation is 3.0-6.0; the solvent is selected from purified water and water for injection; the polymyxin inhalation solution provided by this invention has a simple composition, a pH of 3.0-6.0, and is osmotonic, which can reduce bronchospasm and cough caused by polymyxin inhalation solution. Safety evaluation has verified that it has good safety, providing a new option for clinical application.
Owner:THE FOURTH HOSPITAL OF HEBEI MEDICAL UNIVERSITY (HEBEI CANCER HOSPITAL) +1

A kind of revenacin inhalation solution and preparation method

The present invention provides a refenacin inhalation solution and a preparation method thereof, wherein the refenacin inhalation solution comprises refenacin at a concentration of 130-180 μg / ml, a buffer stabilizer at a concentration of 5-18 mM, a stabilizer at a concentration of 1.8-3.2 g / L, and a solvent, and the solution pH is 4.9-5.2, and the stabilizer is at least one of sodium gluconate, L-fucose, and acetylcysteine. The present invention can significantly improve the stability of the refenacin inhalation solution under ultrasonic atomization, has good storage stability, and has a better lung deposition rate effect; the preparation process is simple to operate and has low production cost, and is easy to industrialize.
Owner:LANGTIAN PHARM (HUBEI) CO LTD +1

Rafenasin inhalation solution composition and preparation method thereof

The invention provides a rafenasin inhalation solution composition and a preparation method thereof. The rafenasin inhalation solution composition is prepared from the following components: rafenasin, a buffer pair, sodium chloride, hydrochloric acid or sodium hydroxide and water, wherein the acidic compound of the buffer pair is one or more of phosphoric acid, acetic acid, boric acid, gallic acid, cysteine, glycolic acid, malonic acid, succinic acid, glutaric acid, fumaric acid, malic acid, tartaric acid and benzoic acid. In the technical scheme, the refenasin inhalation solution composition uses a buffer pair except citric acid, so that the stability of the solution is improved, the composition can tolerate excessive killing and sterilization, the safety is higher, and the production cost is lower.
Owner:HANGZHOU JIANDONG WEIYE MEDICINE CO LTD